Table 3 Treatment- and health-related characteristics of adolescents and viral suppression
Characteristics | Achieved viral suppression (n = 131) | No viral suppression (n = 69) | |||
|---|---|---|---|---|---|
n | % | n | % | ||
Viral suppression | Men |   63 | 48.0 | 41 | 59.0 |
|  | Women |   68 | 52.0 | 28 | 41.0 |
Years on ART (years) | 0–2 |   28 | 21.4 |   7 | 10.1 |
3–5 |   36 | 27.5 | 23 | 33.3 | |
More than 5 |   67 | 51.1 | 39 | 56.5 | |
CD4 count at initiation (cells/mL) | More than 500 |   44 | 33.6 | 10 | 14.5 |
200–499 |   30 | 22.9 | 15 | 21.7 | |
Less than 200 |   22 | 16.8 | 21 | 30.4 | |
Missing |   35 | 26.7 | 23 | 33.3 | |
Adherence status | Good > 95% | 111 | 84.7 | 49 | 71.0 |
Fair/poor < 95% |   20 | 15.3 | 20 | 29.0 | |
History of treatment failure | Yes |   10 |  7.6 | 19 | 27.5 |
No | 121 | 92.4 | 50 | 72.5 | |
WHO clinical stage | I | 116 | 88.5 | 58 | 84.1 |
II |     3 |  2.3 |   3 |  4.3 | |
III |     8 |  6.1 |   8 | 11.6 | |
IV |     4 |  3.1 |  |  | |
Nutritional status | Normal | 118 | 90.0 | 65 | 94.2 |
MAM |     9 |  6.9 |   4 |  5.8 | |
SAM |     4 |  3.1 |  |  | |
Regimen | AZT + 3TC + EFV |     7 | 35.9 | 29 | 42.0 |
AZT + 3TC + NVP |   77 | 58.8 | 39 | 56.5 | |
ABC + 3TC + EFV |     7 |  5.3 |   1 | 1.5 | |